Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Roch Laboratories history
Roch Laboratories company history timeline
The United States branch had been established in 1905, and Bobst's regime had been a resounding success: Under his leadership the company introduced Allonal, a pain reliever, which became the company's first million-dollar product.
The following year, 1920, the company asked shareholders to double their subscriptions.
The year 1920 also marked the death of Fritz Hoffmann-La Roche.
A PhD graduate in political economics she has worked at Roche Basel for about a year before accepting a post in Tokyo, where the company formed a subsidiary in 1925.
Alice Keller, a 30-year-old native of Basel, boards ship to Japan in 1926.
Barell obtained a process for synthesizing vitamin C as early as 1933.
In 1934, it became the first company to mass-produce synthetic vitamin C, under the brand name Redoxon.
When she returns in 1939, Keller has risen to the senior executive ranks of Direktorin – a sensational achievement for the times.
1944: Elmer Bobst resigns.
Emil Barell died in 1953 at the age of 79.
In 1956, the first antidepressant, iproniazid, was accidentally created during an experiment while synthesizing isoniazid.
In 1957 it introduced the class of tranquilizers known as benzodiazepines (with Valium and Rohypnol being the best-known members). Roche has also produced various HIV tests and antiretroviral drugs.
Librium was introduced in 1960.
1963: The company introduces Valium and it exceeds Librium in popularity.
1965: Caflisch dies and Adolf Jann assumes control of the company.
Later successes included vitamins A and E. In 1971 the company enjoyed between 50 and 70 percent of the world market for vitamins, and production continued to grow.
By 1971, some 500 million patients had used one or the other of the drugs, generating an estimated US$2 billion in sales.
In 1973, US$500 million of the US$1.2 billion volume at Roche was attributable to the sale of Valium and Librium.
In 1976 a poison cloud of TCDD, a dioxin found in Agent Orange, escaped from Icmesa, an Italian chemical factory owned by Roche.
In 1989, the company transformed its businesses into true divisions, which began to operate like independent companies.
Further strengthening its position in the worldwide healthcare market, in 1991, it purchased Nicholas, a European-based producer of nonprescription medicines.
Roche acquires the worldwide marketing rights to the polymerase chain reaction (PCR) from Cetus Corporation in 1991.
1998: Franz Humer becomes chief executive officer.
Inhibace was the first Roche product designed with the aid of computer modeling techniques and won the 1999 Prix Galien, Roche's fourth such award.
In 1999, Roche inaugurated its new R&D facility in Basel.
Other 2001 partnerships included those forged with the Mayo Clinic, Combinatrix Corporation, and Millenium Pharmaceuticals, Inc. in the United States; deCODE genetics in Iceland; Prionics Inc. in Switzerland; and Innogenetics NV in Belgium.
Franz Humer, who had been head of the Pharmaceuticals division since 1995, was elected chief executive officer in 1998, replacing Fritz Gerber, who remained president of the board. It also acquired the rest of Genentech and, in 2001, acquired Amira Medical, a corporation active in the diabetes monitoring business.
In 2007 Roche receives the first Financial Times Citi Private Bank Environment Award for the greatest improvement in carbon efficiency by a large enterprise both on a European and a global level.
Genentech became a wholly owned subsidiary group of Roche on 25 March 2009.
The cobas 8000 diagnostics system launches in 2009.
In 2011, the company received the ISPE Facility of the Year Award for Process Innovation for Roche’s “MyDose” Clinical Supply project.
Rate Roch Laboratories' efforts to communicate its history to employees.
Roch Laboratories jobs
Do you work at Roch Laboratories?
Is Roch Laboratories' vision a big part of strategic planning?
Zippia gives an in-depth look into the details of Roch Laboratories, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Roch Laboratories. The employee data is based on information from people who have self-reported their past or current employments at Roch Laboratories. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Roch Laboratories. The data presented on this page does not represent the view of Roch Laboratories and its employees or that of Zippia.
Roch Laboratories may also be known as or be related to Roch Laboratories.